JP2023533504A - バイオフィルムの処置および予防のための併用療法 - Google Patents

バイオフィルムの処置および予防のための併用療法 Download PDF

Info

Publication number
JP2023533504A
JP2023533504A JP2022581467A JP2022581467A JP2023533504A JP 2023533504 A JP2023533504 A JP 2023533504A JP 2022581467 A JP2022581467 A JP 2022581467A JP 2022581467 A JP2022581467 A JP 2022581467A JP 2023533504 A JP2023533504 A JP 2023533504A
Authority
JP
Japan
Prior art keywords
seq
polypeptide
antibody
box
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022581467A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533504A5 (https=
JPWO2022010942A5 (https=
Inventor
スティーブン ディー． グッドマン，
ローレン オー． バカレッツ，
Original Assignee
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル filed Critical リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル
Publication of JP2023533504A publication Critical patent/JP2023533504A/ja
Publication of JP2023533504A5 publication Critical patent/JP2023533504A5/ja
Publication of JPWO2022010942A5 publication Critical patent/JPWO2022010942A5/ja
Priority to JP2025173218A priority Critical patent/JP2026016462A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1242—Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2022581467A 2020-07-07 2021-07-06 バイオフィルムの処置および予防のための併用療法 Pending JP2023533504A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025173218A JP2026016462A (ja) 2020-07-07 2025-10-14 バイオフィルムの処置および予防のための併用療法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063049065P 2020-07-07 2020-07-07
US63/049,065 2020-07-07
US202163175487P 2021-04-15 2021-04-15
US63/175,487 2021-04-15
PCT/US2021/040576 WO2022010942A2 (en) 2020-07-07 2021-07-06 Combination therapies for the treatment and prevention of biofilms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025173218A Division JP2026016462A (ja) 2020-07-07 2025-10-14 バイオフィルムの処置および予防のための併用療法

Publications (3)

Publication Number Publication Date
JP2023533504A true JP2023533504A (ja) 2023-08-03
JP2023533504A5 JP2023533504A5 (https=) 2024-05-28
JPWO2022010942A5 JPWO2022010942A5 (https=) 2024-05-28

Family

ID=79553736

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022581467A Pending JP2023533504A (ja) 2020-07-07 2021-07-06 バイオフィルムの処置および予防のための併用療法
JP2025173218A Pending JP2026016462A (ja) 2020-07-07 2025-10-14 バイオフィルムの処置および予防のための併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025173218A Pending JP2026016462A (ja) 2020-07-07 2025-10-14 バイオフィルムの処置および予防のための併用療法

Country Status (7)

Country Link
US (1) US20230272054A1 (https=)
EP (1) EP4178359A4 (https=)
JP (2) JP2023533504A (https=)
CN (1) CN116096239B (https=)
AU (1) AU2021305167A1 (https=)
CA (1) CA3183196A1 (https=)
WO (1) WO2022010942A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120230733B (zh) * 2025-06-03 2025-07-29 山东三元生物科技股份有限公司 一种基于Spytag/SpyCatcher环化修饰的蔗糖磷酸化酶突变体及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018129078A1 (en) * 2017-01-04 2018-07-12 Research Institute At Nationwide Children's Hospital Dnabii vaccines and antibodies with enhanced activity
WO2018170178A1 (en) * 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
WO2020006528A2 (en) * 2018-06-29 2020-01-02 Research Institute At Nationwide Children's Hospital Compositions and methods for mediating eps
WO2020072993A1 (en) * 2018-10-05 2020-04-09 Research Institute At Nationwide Children's Hospital Hmgb1 protein derivatives for the removal of biofilms cross-reference to related application

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012010793A (es) * 2010-03-29 2013-05-09 Univ Southern California Composiciones y metodos para la eliminacion de biopeliculas.
US10722577B2 (en) * 2012-05-25 2020-07-28 Sloan Kettering Institute For Cancer Research Methods for treating GI syndrome and graft versus host disease
US20160340650A1 (en) * 2015-05-21 2016-11-24 Batu Biologics, Inc. Blood derived immune stimulatory compositions
WO2020038963A1 (en) * 2018-08-21 2020-02-27 Modiquest B.V. Antibodies binding to citrullinated histone 2a and/or 4
EA202191176A1 (ru) * 2018-10-31 2021-07-28 Делиниа, Инк. Поливалентные модуляторы регуляторных т-клеток
WO2021007260A2 (en) * 2019-07-08 2021-01-14 Research Institute At Nationwide Children's Hospital Antibody compositions for disrupting biofilms

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018129078A1 (en) * 2017-01-04 2018-07-12 Research Institute At Nationwide Children's Hospital Dnabii vaccines and antibodies with enhanced activity
WO2018170178A1 (en) * 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
WO2020006528A2 (en) * 2018-06-29 2020-01-02 Research Institute At Nationwide Children's Hospital Compositions and methods for mediating eps
WO2020072993A1 (en) * 2018-10-05 2020-04-09 Research Institute At Nationwide Children's Hospital Hmgb1 protein derivatives for the removal of biofilms cross-reference to related application

Also Published As

Publication number Publication date
EP4178359A2 (en) 2023-05-17
CN116096239A (zh) 2023-05-09
CA3183196A1 (en) 2022-01-13
AU2021305167A1 (en) 2023-02-02
WO2022010942A2 (en) 2022-01-13
EP4178359A4 (en) 2024-10-09
US20230272054A1 (en) 2023-08-31
WO2022010942A3 (en) 2022-03-24
CN116096239B (zh) 2025-09-02
JP2026016462A (ja) 2026-02-03

Similar Documents

Publication Publication Date Title
US12239763B2 (en) Peptides and antibodies for the removal of biofilms
JP7627255B2 (ja) バイオフィルムを破壊するための抗体組成物
US12419944B2 (en) DNABII vaccines and antibodies with enhanced activity
JP7661008B2 (ja) バイオフィルム関連障害の処置のための抗体断片
KR20210070331A (ko) 생물막 제거를 위한 hmgb1 단백질 유도체
JP2026016462A (ja) バイオフィルムの処置および予防のための併用療法
RU2851685C2 (ru) Композиции антител для разрушения биопленок
HK40111331A (en) Antibody compositions for disrupting biofilms
HK1255383B (en) Peptides and antibodies for the removal of biofilms

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251014

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260414